Coronavirus Update: WHO Suspends Hydroxychloroquine Trial, Novavax Launches Phase I/II Vaccine Study
Plus: Medicago Plans Vaccine Trials After Positive Early Results
Mounting evidence that President Trump's 'game changer' does more harm than good for COVID-19 patients. Novovax and Medicago among the latest vaccine developers to report progress.
You may also be interested in...
Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Experts fear Trump’s unregulated use of the malaria drug is dangerous, and muddies the waters around research which could still find chloroquine useful in preventing SARS-CoV-2 infection.